Recombinant Anti-VEGFR2 Fully Human Monoclonal Antibody(Jingyitaixiang Technology Development)

重组抗VEGFR2全人源单克隆抗体

Report date: 2024/11/25 20:00:28

Base Information

Drug NameRecombinant Anti-VEGFR2 Fully Human Monoclonal Antibody(Jingyitaixiang Technology Development)
Drug Alias Name重组抗VEGFR2全人源单克隆抗体（JY025）注射液JY-025
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Jingyitaixiang Technology Development Co LtdBeijing Eastern Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Jingyitaixiang Technology Development Co LtdBeijing Eastern Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A